Sacituzumab Govitecan vs Treatment of Physician’s Choice: Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients with HR+/HER2– Metastatic Breast Cancer

Hope Rugo, MD discusses key data updates on the TROPiCS-02 study on sacituzumab govitecan in patients with endocrine-resistant, HR+/HER2- advanced breast cancer that were recently presented at the 2022 San Antonio Breast Cancer Symposium.

Related Videos
Related Content

WHO Outlines New Framework for Early Detection and Management of Breast Cancer

February 3rd 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Breast Cancer Expert Focuses on Decoding Biomarkers

February 2nd 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer

January 30th 2023

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 27th 2023

WHO Outlines New Framework for Early Detection and Management of Breast Cancer

February 3rd 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Breast Cancer Expert Focuses on Decoding Biomarkers

February 2nd 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer

January 30th 2023

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 27th 2023

WHO Outlines New Framework for Early Detection and Management of Breast Cancer

February 3rd 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Breast Cancer Expert Focuses on Decoding Biomarkers

February 2nd 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer

January 30th 2023

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 27th 2023
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact